Botanix Pharmaceuticals Ltd has released a press release.
Botanix Pharmaceuticals Half Year Report
Filed with ASX ·
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Botanix Pharmaceuticals Limited on 6ix
Earlier from Botanix Pharmaceuticals
- December 2023 Quarterly Activities Report and Appendix 4C
- NDA Resubmission Accepted and Approval Date Confirmed
- Botanix Resubmission of NDA for Sofdra Completed
- Successful Completion of Human Factors Study
- FDA Confirms Approach to Sofdra NDA Resubmission
Later from Botanix Pharmaceuticals
- S&P DJI Announces March 2024 Quarterly Rebalance
- March 2024 Quarterly Activities Report and Appendix 4C
- Final Sofdra Labelling Discussions with FDA
- FDA Approves Sofdra
- Botanix $70 Million Institutional Capital Raising
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals